Trial Profile
An open-label, phase I dose escalation study of afatinib combined with paclitaxel and bevacizumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jul 2017 New trial record